Clinical Trial Update: CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) [Phase 1]

View source ↗

Summary

A Phase 1 study from Stanford evaluating a CAR-T cell therapy called ceLL to eradicate active residual disease in diffuse large B-cell lymphoma; the trial is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CAR-T ceLL

Snippet

Sponsor: Stanford University | Conditions: Large-cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING